Výsledky vyhledávání - "Lisa T, Dooley"

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Autor: Craig L, Leonardi, Alexa B, Kimball, Kim A, Papp, Newman, Yeilding, Cynthia, Guzzo, Yuhua, Wang, Shu, Li, Lisa T, Dooley, Kenneth B, Gordon, P, Ghislain

Publikováno v: The Lancet. 371:1665-1674

Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis.In this phase III, parallel, double-blind, placebo-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562a2cebbe7cc3cc7657c3b2742514a2
https://doi.org/10.1016/s0140-6736(08)60725-4

Zobrazit plný text záznamu

Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis

Autor: Gerald G. Krueger, Cynthia Guzzo, Dafna D. Gladman, Songkai Yan, A. Beutler, Arthur Kavanaugh, C Antoni, Lisa T. Dooley, Mohan Bala

Publikováno v: Annals of the Rheumatic Diseases. 65:471-477

To evaluate the effect of infliximab on health related quality of life (HRQoL) and physical function in patients with active psoriatic arthritis (PsA) in the IMPACT 2 trial.200 patients with PsA unresponsive to conventional treatment were randomised

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8614de0410735ab486c396f2b2daae5d
https://doi.org/10.1136/ard.2005.040196

Zobrazit plný text záznamu

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial

Autor: A. Menter, Kenneth B. Gordon, K. Patel, Steven R. Feldman, Alice B. Gottlieb, M. Bala, R. Evans, Shu Li, Lisa T. Dooley, C. Guzzo

Publikováno v: British Journal of Dermatology. 152:954-960

Summary Background Psoriasis is a chronic disease that significantly diminishes the health-related quality of life (HRQOL). Infliximab is a chimeric, tumour necrosis factor α monoclonal antibody that has been shown to improve the signs and symptoms

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ae66b704cfd934c75f99f902554d0b9
https://doi.org/10.1111/j.1365-2133.2005.06510.x

Zobrazit plný text záznamu

Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial

Autor: Alice B. Gottlieb, Mohan Bala, Lisa T. Dooley, Shu Li, Cynthia Guzzo, Colleen Marano, Robert Evans, Daniel G. Baker, Alan Menter

Publikováno v: Journal of the American Academy of Dermatology. 51:534-542

Tumor necrosis factor-alpha is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis factor-alpha, blocking its biologic activity.The purpose of this study was to access the eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0c72ddf2f3c8e85060421a8075ad98e
https://doi.org/10.1016/j.jaad.2004.02.021

Zobrazit plný text záznamu

Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris

Autor: Alice B. Gottlieb, Carrie L. Wagner, Ahsan A. Abdulghani, Pat Romano, Salman Masuda, Umesh Chaudhari, Lisa T. Dooley, Adedigbo A. Fasanmade, Rallapalli Ramamurthi

Publikováno v: Journal of the American Academy of Dermatology. 48:68-75

Objective: Infliximab monotherapy provided a rapid and high degree of clinical benefit in patients with moderate to severe psoriasis in a previously conducted trial. Herein we describe the pharmacodynamic and pharmacokinetic results observed in this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8328c3790a3dac2714389d31a262dd15
https://doi.org/10.1067/mjd.2003.10

Zobrazit plný text záznamu

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Autor: U Chaudhari, Lisa T. Dooley, P Romano, LD Mulcahy, Daniel G. Baker, Alice B. Gottlieb

Publikováno v: The Lancet. 357:1842-1847

Summary Background Currently available treatments for moderate to severe psoriasis are either incompletely effective in some patients, or are associated with toxic effects. Since tumour necrosis factor α (TNF-α) is thought to have a role in the pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f3062f840692c5c390542328d50fa20
https://doi.org/10.1016/s0140-6736(00)04954-0

Zobrazit plný text záznamu

Plný text ve formátu HTML

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Autor: Alan Menter, Roseanne Fidelus-Gort, Bruce Strober, B. Zhou, Shu Li, Newman Yeilding, Peter C.M. van de Kerkhof, Christopher E.M. Griffiths, Neil H. Goldstein, Cynthia Guzzo, Vincent T. Ho, Lisa T. Dooley, Yichuan Xia

Publikováno v: The New England Journal of Medicine, 362, 118-28
The New England Journal of Medicine, 362, 2, pp. 118-28

Contains fulltext : 89832.pdf (Publisher’s version ) (Closed access) BACKGROUND: Biologic agents offer a range of new therapeutic options for patients with psoriasis; however, the relative benefit-risk profiles of such therapies are not well known.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1a17e26f0bf3f1d633a704a30f91b28
http://hdl.handle.net/2066/89832

Zobrazit plný text záznamu

Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis

Autor: Steven R. Feldman, Ying Wu, Shu Li, Cynthia Guzzo, Alice B. Gottlieb, Mohan Bala, Lisa T. Dooley, Alan Menter, David Eisenberg

Publikováno v: The British journal of dermatology. 159(3)

Summary Background Psoriasis affects patients both physically and psychologically. Objectives To investigate the effect of comorbidities on health-related quality of life (HRQoL) and to determine whether infliximab improved HRQoL in the presence of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f32c1cb34e2c7d74424edd3f4c849641
https://pubmed.ncbi.nlm.nih.gov/18627375

Zobrazit plný text záznamu

Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2

Autor: C. Birbara, Gerald G. Krueger, Cynthia Guzzo, K. de Vlam, D. Halter, P. Geusens, Dafna D. Gladman, D. van der Heijde, A. Kavanaugh, B. Zhou, A. Beutler, C Antoni, Lisa T. Dooley

Publikováno v: Arthritis and rheumatism. 56(8)

Objective To evaluate the effect of infliximab on progression of structural damage over 1 year in patients with active psoriatic arthritis (PsA) enrolled in the Induction and Maintenance Psoriatic Arthritis Clinical Trial 2. Methods In this double-bl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a930bf352d0f94469bd13038244354eb
https://pubmed.ncbi.nlm.nih.gov/17665424

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání